Sep.16,2025
FIMECS to Present at the 23rd Discovery on Target
News release
Kanagawa, Japan, 16th September 2025 – FIMECS, Inc. (“FIMECS”), a private biotechnology company pioneering a new class of medicines through targeted protein degradation, today announced that Dr. Shigeru Furukubo, VP Chemistry will present the company’s latest research at the upcoming 23rd Discovery on Target, taking place in Boston, MA, USA.
Presentation Details:
Title: A Highly Productive Platform for Discovery of Targeted Protein Degraders
Presenter: Dr. Shigeru Furukubo
Time and Date: 3:50 pm – 4:20 pm, Thursday, September 25th, 2025
FIMECS will showcase RaPPIDS™, its proprietary platform designed to accelerate degrader discovery. This innovative platform enables the rapid generation of heterobifunctional degrader molecules and the identification of novel E3 ligase binders through a phenotypic-first strategy. Dr. Furukubo will present case studies from ongoing research programs and highlight how RaPPIDS™ accelerates the identification and optimization of degrader molecules with suitable DMPK profiles.
About FIMECS, Inc.
FIMECS, Inc. is a wholly-owned subsidiary of RaQualia Pharma (TSE:4579). The company is developing a new class of drugs based on targeted protein degradation for the currently ‘undruggable’ targets in immuno-oncology and oncology areas. By integrating proprietary E3 ligase binders and the RaPPIDS™ platform, FIMECS can discover drug candidates that induce the degradation of disease-relevant proteins. This drug discovery platform enable the company to deliver innovative drugs to patients worldwide through both internal and collaboration projects. https://www.fimecs.com/eng/
# # #
FIMECS, Inc. Media and Investor Contact:
FIMECS, Inc.
26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan
Tel: +81-466-96-0261
Email: info@fimecs.com